Last reviewed · How we verify
Mayzent
At a glance
| Generic name | Mayzent |
|---|---|
| Sponsor | Novartis Pharmaceuticals |
| Target | Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Approved indications
- Relapsing remitting multiple sclerosis
- Secondary progressive multiple sclerosis
Common side effects
Key clinical trials
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (Phase 4)
- Survey Among Healthcare Professionals and MS Patients/Caregivers in Selected European Countries to Evaluate the Knowledge Required for the Safe Use of Mayzent (N/A)
- A Real-World, Retrospective, Multicenter Study to Assess the Effectiveness and Safety of Mayzent® (Siponimod) in Chinese Patients With Relapsing Forms of Multiple Sclerosis (N/A)
- Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study (N/A)
- Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis) (N/A)
- Managed Access Program (MAP) to Provide Access to Siponimod Treatment for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With no Satisfactory Alternative Treatment (N/A)
- Observational Retrospective Study to Assess the Use of Siponimod (Mayzent) on Patients With Secondary Progressive Multiple Sclerosis in Clinical Practice in Spain - RESYZE Study (N/A)
- Immune Response to SARS-CoV2 Vaccinations in Treated MS Patients Compared to Controls (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mayzent CI brief — competitive landscape report
- Mayzent updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI